Canada markets close in 28 minutes

Asarina Pharma AB (publ) (APS.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.0002-0.0004 (-66.67%)
As of 09:19AM CEST. Market open.

Asarina Pharma AB (publ)

Karolinska Institutet Science Park
Fogdevreten 2
Solna 171 65
46 8 52 48 44 82

Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter Nordkild M.D.CEO & Chief Medical Officer2.69MN/A1955
Mr. Jakob Dynnes Hansen M.Sc., MBAChief Financial OfficerN/AN/A1955
Mr. Torbjörn Bäckström M.D., Ph.D.Chairman of Scientific Advisory BoardN/AN/A1948
Mark DuBoisCommunications ManagerN/AN/AN/A
Mr. Otto Skolling M.ScChief Business OfficerN/AN/A1961
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its's product is Sepranolone, which is used for the treatment of allopregnanolone-induced stress- and compulsivity-driven disorders from Tourette syndrome to Obsessivecompulsive disorder syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. The company was incorporated in 2005 and is based in Solna, Sweden.

Corporate Governance

Asarina Pharma AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.